Adding immunotherapy to chemo after stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding immunotherapy to standard chemotherapy after surgery helps prevent stomach or gastroesophageal junction cancer from coming back. It is for people who already had chemotherapy before surgery and have HER2-negative adenocarcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with adenocarcinoma of the stomach or gastroesophageal junction (not other types like squamous cell).
- Your cancer does not have extra HER2 protein (HER2-negative).
- You have already received 3 to 4 cycles of chemotherapy before surgery.
- After surgery, your doctor believes further treatment is needed and the study treatment is right for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It is for people whose cancer has been fully removed and who need further treatment.
This trial tests different adjuvant treatments for patients who had stomach or gastroesophageal junction cancer, received chemotherapy with immunotherapy before surgery, and had a complete response (no cancer left) in the surgical sample. It aims to find which treatment works best to prevent the cancer from coming back.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy (SOX) as a first treatment for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this combination can help shrink the tumor before surgery.
This trial tests whether adding a short course of radiation to a combination of immunotherapy (PD-1 inhibitor) and chemotherapy (SOX) before surgery helps treat advanced stomach or GEJ cancer. It aims to see if the extra radiation makes the treatment more effective.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial studies giving immunotherapy together with chemotherapy and radiation before surgery for esophagogastric junction cancer. It aims to shrink the tumor and improve outcomes for people with early locally advanced, HER2-negative disease.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.